Precision Medicine in Oncology®

Rituximab dose should be based on age and sex.

Drugs that inhibit the DNA repair enzyme poly(ADP-ribose) polymerase (PARP) have been shown to be effective in treating ovarian, breast, and prostate cancers in patients with inherited BRCA mutations. In broadening the therapeutic scope of PARP inhibitors beyond germline BRCA-mutated cancers.

As one of the most significant predictors of hereditary breast and ovarian cancer, the BRCA1/2 genes have become the poster child for genetic testing, thrust into the limelight by a high-profile court battle and a celebrity's disclosure.

What patients with cancer perceive as relevant clinical outcomes, and how these outcomes are assessed, is important in the provision of routine care and in the arena of clinical trials.

Based on a current laboratory research project, Zarah Dulce F. Lucas, MD, discusses microRNAs and their potential to predict brain metastases in patients with triple-negative and HER2-positive breast cancer.

PARP inhibitors represent an exciting new class of anticancer agents and are currently being evaluating in phase III for a number of different indications.